US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
SE370449B
(en)
|
1970-08-29 |
1974-10-14 |
Philips Nv |
|
JPS5334319B2
(en)
|
1971-12-28 |
1978-09-20 |
|
|
JPS5717624B2
(en)
|
1974-04-17 |
1982-04-12 |
|
|
US4769320A
(en)
|
1982-07-27 |
1988-09-06 |
New England Medical Center Hospitals, Inc. |
Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations
|
JPS58201994A
(en)
|
1982-05-21 |
1983-11-25 |
Hideaki Hagiwara |
Method for producing antigen-specific human immunoglobulin
|
US4689299A
(en)
|
1982-09-30 |
1987-08-25 |
University Of Rochester |
Human monoclonal antibodies against bacterial toxins
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
JPH06104071B2
(en)
|
1986-08-24 |
1994-12-21 |
財団法人化学及血清療法研究所 |
Factor IX Monoclonal antibody specific for conformation
|
US4801687A
(en)
|
1986-10-27 |
1989-01-31 |
Bioprobe International, Inc. |
Monoclonal antibody purification process using protein A
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
US5670373A
(en)
|
1988-01-22 |
1997-09-23 |
Kishimoto; Tadamitsu |
Antibody to human interleukin-6 receptor
|
CA1341152C
(en)
|
1988-01-22 |
2000-12-12 |
Tadamitsu Kishimoto |
Receptor protein for human b cell stimulatory factor-2
|
US5322678A
(en)
|
1988-02-17 |
1994-06-21 |
Neorx Corporation |
Alteration of pharmacokinetics of proteins by charge modification
|
US5126250A
(en)
|
1988-09-28 |
1992-06-30 |
Eli Lilly And Company |
Method for the reduction of heterogeneity of monoclonal antibodies
|
IL91778A
(en)
|
1988-09-28 |
1994-10-07 |
Lilly Co Eli |
Method fo rthe reduction of heterogeneity of monoclonal antibodies
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5202253A
(en)
|
1988-12-30 |
1993-04-13 |
Oklahoma Medical Research Foundation |
Monoclonal antibody specific for protein C and antibody purification method
|
JP2898064B2
(en)
|
1989-08-03 |
1999-05-31 |
忠三 岸本 |
Human gp130 protein
|
JPH0636741B2
(en)
|
1989-11-08 |
1994-05-18 |
帝人株式会社 |
Method for separating human protein C
|
JPH03155795A
(en)
|
1989-11-13 |
1991-07-03 |
Chuzo Kishimoto |
Mouse-interleukin-6 receptor protein
|
US5210075A
(en)
|
1990-02-16 |
1993-05-11 |
Tanabe Seiyaku Co., Ltd. |
Interleukin 6 antagonist peptides
|
WO1991012023A2
(en)
|
1990-02-16 |
1991-08-22 |
Boston Biomedical Research Institute |
Hybrid reagents capable of selectively releasing molecules into cells
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
DK0585287T3
(en)
|
1990-07-10 |
2000-04-17 |
Cambridge Antibody Tech |
Process for producing specific binding pair elements
|
ES2246502T3
(en)
|
1990-08-29 |
2006-02-16 |
Genpharm International, Inc. |
TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
|
WO1993012227A1
(en)
|
1991-12-17 |
1993-06-24 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
ES2134212T3
(en)
|
1991-04-25 |
1999-10-01 |
Chugai Pharmaceutical Co Ltd |
HUMAN ANTIBODY RECONSTITUTED AGAINST THE RECEIVER OF INTERLEUKIN 6 HUMAN.
|
US6136310A
(en)
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
DK0605522T3
(en)
|
1991-09-23 |
2000-01-17 |
Medical Res Council |
Process for producing humanized antibodies
|
DK1024191T3
(en)
|
1991-12-02 |
2008-12-08 |
Medical Res Council |
Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries
|
CA2131151A1
(en)
|
1992-03-24 |
1994-09-30 |
Kevin S. Johnson |
Methods for producing members of specific binding pairs
|
ATE381614T1
(en)
|
1992-07-24 |
2008-01-15 |
Amgen Fremont Inc |
FORMATION OF XENOGENE ANTIBODIES
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
US5648267A
(en)
|
1992-11-13 |
1997-07-15 |
Idec Pharmaceuticals Corporation |
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
|
CA2161351C
(en)
|
1993-04-26 |
2010-12-21 |
Nils Lonberg |
Transgenic non-human animals capable of producing heterologous antibodies
|
WO1994029471A1
(en)
|
1993-06-10 |
1994-12-22 |
Genetic Therapy, Inc. |
Adenoviral vectors for treatment of hemophilia
|
GB9313509D0
(en)
|
1993-06-30 |
1993-08-11 |
Medical Res Council |
Chemisynthetic libraries
|
IL107742A0
(en)
|
1993-11-24 |
1994-02-27 |
Yeda Res & Dev |
Chemically-modified binding proteins
|
CA2177367A1
(en)
|
1993-12-03 |
1995-06-08 |
Andrew David Griffiths |
Recombinant binding proteins and peptides
|
DE4419399C1
(en)
|
1994-06-03 |
1995-03-09 |
Gsf Forschungszentrum Umwelt |
Process for the preparation of heterologous bispecific antibodies
|
US5945311A
(en)
|
1994-06-03 |
1999-08-31 |
GSF--Forschungszentrumfur Umweltund Gesundheit |
Method for producing heterologous bi-specific antibodies
|
US8017121B2
(en)
|
1994-06-30 |
2011-09-13 |
Chugai Seiyaku Kabushika Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
US6309636B1
(en)
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
EP2077120A3
(en)
|
1994-10-07 |
2009-07-15 |
Chugai Seiyaku Kabushiki Kaisha |
Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient
|
CZ298790B6
(en)
|
1994-10-21 |
2008-01-30 |
Kishimoto@Tadamitsu |
Pharmaceutical composition for prevention or treatment of cachexia
|
IT1274350B
(en)
|
1994-12-06 |
1997-07-17 |
Angeletti P Ist Richerche Bio |
INTERLEUCHINA-6 (IL-6) ANTAGONISTS, WHICH CONSIST OF SOLUBLE FORMS OF THE ALFA RECEPTOR OF IL-6, CHANGED IN THE INTERFACE THAT LINKS TO GP 130
|
IT1274782B
(en)
|
1994-12-14 |
1997-07-24 |
Angeletti P Ist Richerche Bio |
METHOD FOR SELECTING SUPERAGONISTS, ANTAGONISTS AND SUPERANTAGONISTS OF HORMONES OF WHICH RECEPTOR COMPLEX IS PART OF GP 130
|
US6485943B2
(en)
|
1995-01-17 |
2002-11-26 |
The University Of Chicago |
Method for altering antibody light chain interactions
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US6060293A
(en)
|
1995-03-31 |
2000-05-09 |
Prokyon Aps |
Resonance driven changes in chain molecule structure
|
ES2304786T3
(en)
|
1995-04-27 |
2008-10-16 |
Amgen Fremont Inc. |
ANTI-IL-8 HUMAN ANTIBODIES, DERIVED FROM IMMUNIZED XENORATONES.
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
Human antibodies derived from immunized xenomice
|
US5571513A
(en)
|
1995-05-31 |
1996-11-05 |
The Board Of Regents Of The University Of Oklahoma |
Anti-gp130 monoclonal antibodies
|
US5830478A
(en)
|
1995-06-07 |
1998-11-03 |
Boston Biomedical Research Institute |
Method for delivering functional domains of diphtheria toxin to a cellular target
|
US5783186A
(en)
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
TWI240627B
(en)
|
1996-04-26 |
2005-10-01 |
Chugai Pharmaceutical Co Ltd |
Erythropoietin solution preparation
|
CA2259163C
(en)
|
1996-07-19 |
2004-07-06 |
Amgen Inc. |
Nt-3 and bdnf analogs having improved circulating life and/or absorption
|
US5990286A
(en)
|
1996-12-18 |
1999-11-23 |
Techniclone, Inc. |
Antibodies with reduced net positive charge
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
DE69839992D1
(en)
|
1997-03-21 |
2008-10-23 |
Chugai Pharmaceutical Co Ltd |
Prophylactic or therapeutic agents for the treatment of multiple sclerosis, with antagonist anti-IL6 receptor antibodies as the active ingredient
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
US20020187150A1
(en)
|
1997-08-15 |
2002-12-12 |
Chugai Seiyaku Kabushiki Kaisha |
Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
|
CA2296322A1
(en)
|
1997-08-15 |
1999-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Preventives and/or remedies for systemic lupus erythematosus containing anti-il-6 receptor antibody as the active ingredient
|
RU2221809C2
(en)
|
1997-10-03 |
2004-01-20 |
Тугаи Сейяку Кабусики Кайся |
Method for preparing natural humanized antibody
|
JP2002505086A
(en)
|
1998-02-25 |
2002-02-19 |
レキシジェン ファーマシューティカルズ コーポレイション |
Enhanced circulating half-life of antibody-based fusion proteins
|
CA2324115C
(en)
|
1998-03-17 |
2008-12-23 |
Chugai Seiyaku Kabushiki Kaisha |
A preventive or therapeutic agent for inflammatory bowel disease comprising il-6 antagonist as an active ingredient
|
SK14812000A3
(en)
|
1998-04-03 |
2001-08-06 |
Chugai Seiyaku Kabushiki Kaisha |
HUMANIZED ANTIBODY AGAINST HUMAN TISSUE FACTOR (TF) AND PROCESSì (54) FOR CONSTRUCTING HUMANIZED ANTIBODY
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
US6475718B2
(en)
|
1998-09-08 |
2002-11-05 |
Schering Aktiengesellschaft |
Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
|
MXPA01005515A
(en)
|
1998-12-01 |
2003-07-14 |
Protein Design Labs Inc |
Humanized antibodies to gamma-interferon.
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6972125B2
(en)
|
1999-02-12 |
2005-12-06 |
Genetics Institute, Llc |
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
SE9903895D0
(en)
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
JP2004511426A
(en)
|
2000-05-03 |
2004-04-15 |
ミュンヘン バイオテク アーゲー |
Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
|
PT2275449T
(en)
|
2000-06-16 |
2016-12-27 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
ES2298273T3
(en)
|
2000-10-25 |
2008-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
PREVENTIVE OR THERAPEUTIC AGENTS AGAINST PSORIASIS CONTAINING AN IL-6 ANTAGONIST AS THEIR ACTIVE INGREDIENT.
|
JP4889187B2
(en)
|
2000-10-27 |
2012-03-07 |
中外製薬株式会社 |
A blood MMP-3 concentration reducing agent comprising an IL-6 antagonist as an active ingredient
|
EP2341060B1
(en)
|
2000-12-12 |
2019-02-20 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
BR0207854A
(en)
|
2001-03-07 |
2004-08-24 |
Merck Patent Gmbh |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
YU80903A
(en)
|
2001-04-13 |
2006-05-25 |
Biogen Inc. |
Antibodies to vla-1
|
US7667004B2
(en)
|
2001-04-17 |
2010-02-23 |
Abmaxis, Inc. |
Humanized antibodies against vascular endothelial growth factor
|
ATE407204T1
(en)
|
2001-06-22 |
2008-09-15 |
Chugai Pharmaceutical Co Ltd |
CELL PROLIFERATION INHIBITORS WITH ANTI-GLYPICAN-3 ANTIBODIES
|
US20040161741A1
(en)
|
2001-06-30 |
2004-08-19 |
Elazar Rabani |
Novel compositions and processes for analyte detection, quantification and amplification
|
US20030049203A1
(en)
|
2001-08-31 |
2003-03-13 |
Elmaleh David R. |
Targeted nucleic acid constructs and uses related thereto
|
CN100374457C
(en)
|
2001-11-14 |
2008-03-12 |
森托科尔公司 |
Anti-IL-6 antibodies, compositions, methods and uses
|
EP1573002A4
(en)
|
2002-02-11 |
2008-07-16 |
Genentech Inc |
Antibody variants with faster antigen association rates
|
JP4364645B2
(en)
|
2002-02-14 |
2009-11-18 |
中外製薬株式会社 |
Antibody-containing solution formulation
|
AR038568A1
(en)
|
2002-02-20 |
2005-01-19 |
Hoffmann La Roche |
ANTI-A BETA ANTIBODIES AND ITS USE
|
EP1510943A4
(en)
|
2002-05-31 |
2007-05-09 |
Celestar Lexico Sciences Inc |
Interaction predicting device
|
DK1512015T3
(en)
|
2002-06-12 |
2009-07-06 |
Genencor Int |
Methods for improving the binding properties of a molecule
|
AU2003256266A1
(en)
|
2002-06-12 |
2003-12-31 |
Genencor International, Inc. |
Methods and compositions for milieu-dependent binding of a targeted agent to a target
|
JP3856734B2
(en)
|
2002-06-28 |
2006-12-13 |
株式会社日立製作所 |
A method for predicting the effectiveness of interferon-beta drug therapy for multiple sclerosis
|
CA2492524A1
(en)
|
2002-08-15 |
2004-02-26 |
Epitomics, Inc. |
Humanized rabbit antibodies
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
PT1562972E
(en)
|
2002-10-15 |
2010-11-10 |
Facet Biotech Corp |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
PT1575517E
(en)
|
2002-12-24 |
2012-05-28 |
Rinat Neuroscience Corp |
Anti-ngf antibodies and methods using same
|
CA2515081A1
(en)
|
2003-02-07 |
2004-08-19 |
Protein Design Labs, Inc. |
Amphiregulin antibodies and their use to treat cancer and psoriasis
|
EP1601697B1
(en)
|
2003-02-28 |
2007-05-30 |
Lonza Biologics plc |
Antibody purification by Protein A and ion exchange chromatography
|
JP4685764B2
(en)
|
2003-04-10 |
2011-05-18 |
アボット バイオセラピューティクス コーポレイション |
Modification of antibody FcRn binding affinity or serum half-life by mutagenesis
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
KR20060027801A
(en)
|
2003-06-05 |
2006-03-28 |
제넨테크, 인크. |
Combination therapy for b cell disorders
|
WO2004113387A2
(en)
|
2003-06-24 |
2004-12-29 |
Merck Patent Gmbh |
Tumour necrosis factor receptor molecules with reduced immunogenicity
|
US20050033029A1
(en)
|
2003-06-30 |
2005-02-10 |
Jin Lu |
Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
|
JP4223346B2
(en)
|
2003-07-18 |
2009-02-12 |
京セラミタ株式会社 |
Image forming apparatus
|
AU2004273791A1
(en)
|
2003-09-05 |
2005-03-31 |
Genentech, Inc. |
Antibodies with altered effector functions
|
JP2005101105A
(en)
|
2003-09-22 |
2005-04-14 |
Canon Inc |
Positioning device, exposure apparatus, and device manufacturing method
|
WO2005035753A1
(en)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
AU2003271186A1
(en)
|
2003-10-14 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
EP1690550B1
(en)
|
2003-10-17 |
2012-08-08 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for mesothelioma
|
US7820800B2
(en)
|
2003-11-05 |
2010-10-26 |
Ares Trading S.A. |
Process for the purification of IL-18 binding protein
|
CA2545603A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
|
EP1701979A2
(en)
|
2003-12-03 |
2006-09-20 |
Xencor, Inc. |
Optimized antibodies that target the epidermal growth factor receptor
|
CA2546054C
(en)
|
2003-12-10 |
2014-05-13 |
Medarex, Inc. |
Interferon alpha antibodies and their uses
|
AR048210A1
(en)
|
2003-12-19 |
2006-04-12 |
Chugai Pharmaceutical Co Ltd |
A PREVENTIVE AGENT FOR VASCULITIS.
|
SV2006001990A
(en)
|
2004-01-09 |
2006-01-30 |
Pfizer |
ANTIBODIES AGAINST MADCAM
|
DE602005020743D1
(en)
|
2004-02-11 |
2010-06-02 |
Warner Lambert Co |
PROCESS FOR TREATING OSTEOARTHRITIS WITH ANTI-IL-6 ANTIBODIES
|
AR048335A1
(en)
|
2004-03-24 |
2006-04-19 |
Chugai Pharmaceutical Co Ltd |
THERAPEUTIC AGENTS FOR INTERNAL EAR DISORDERS CONTAINING AN IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT
|
KR20070035482A
(en)
|
2004-03-24 |
2007-03-30 |
추가이 세이야쿠 가부시키가이샤 |
Therapeutic agent for auris interna disorder containing il-6 antagonist as active ingredient
|
EP3736295A1
(en)
|
2004-03-24 |
2020-11-11 |
Chugai Seiyaku Kabushiki Kaisha |
Subtypes of humanized antibody against interleukin-6 receptor
|
EP2053062A1
(en)
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobin variants outside the Fc region
|
US20050260711A1
(en)
|
2004-03-30 |
2005-11-24 |
Deepshikha Datta |
Modulating pH-sensitive binding using non-natural amino acids
|
WO2005112564A2
(en)
|
2004-04-15 |
2005-12-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Germline and sequence variants of humanized antibodies and methods of making and using them
|
AR049390A1
(en)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
|
CA2568952C
(en)
|
2004-06-18 |
2019-05-21 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
EP1773391A4
(en)
|
2004-06-25 |
2009-01-21 |
Medimmune Inc |
Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
|
ES2372503T3
(en)
|
2004-07-06 |
2012-01-20 |
Bioren, Inc. |
REVISED MUTAGENESIS TO DEVELOP ALTERED POLYPEPTIDES WITH POTENTIATED PROPERTIES.
|
EP1919950A1
(en)
|
2004-07-15 |
2008-05-14 |
Xencor, Inc. |
Optimized fc variants
|
EP1799718A1
(en)
|
2004-09-14 |
2007-06-27 |
National Institute for Biological Standards and Control (NIBSC) |
Vaccine
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
JO3000B1
(en)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
Antibody Formulations.
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
KR101370253B1
(en)
|
2004-10-22 |
2014-03-05 |
암젠 인크 |
Methods for refolding of recombinant antibodies
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
US7632497B2
(en)
|
2004-11-10 |
2009-12-15 |
Macrogenics, Inc. |
Engineering Fc Antibody regions to confer effector function
|
US20090061485A1
(en)
|
2004-12-22 |
2009-03-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
|
ATE461211T1
(en)
|
2004-12-23 |
2010-04-15 |
Novo Nordisk As |
LIGANDS WITH ANTIBODY BINDING AFFINITY
|
EP1833510A4
(en)
|
2004-12-27 |
2010-02-10 |
Progenics Pharmaceuticals Neva |
Orally deliverable and anti-toxin antibodies and methods for making and using them
|
ES2557325T5
(en)
|
2004-12-28 |
2023-11-15 |
Innate Pharma Sa |
Monoclonal antibodies against NKG2A
|
US8716451B2
(en)
|
2005-01-12 |
2014-05-06 |
Kyowa Hakko Kirin Co., Ltd |
Stabilized human IgG2 and IgG3 antibodies
|
WO2006076594A2
(en)
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
GB0502358D0
(en)
|
2005-02-04 |
2005-03-16 |
Novartis Ag |
Organic compounds
|
US10011858B2
(en)
|
2005-03-31 |
2018-07-03 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
DK2824183T3
(en)
|
2005-04-08 |
2020-09-28 |
Chugai Pharmaceutical Co Ltd |
Process for the production of bispecific antibodies
|
JO3058B1
(en)
|
2005-04-29 |
2017-03-15 |
Applied Molecular Evolution Inc |
Anti-IL-6 Antibodies,Compositions,Methods and uses
|
EP1885755A4
(en)
|
2005-05-05 |
2009-07-29 |
Univ Duke |
Anti-cd19 antibody therapy for autoimmune disease
|
SI2573114T1
(en)
|
2005-08-10 |
2016-08-31 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
ES2534760T3
(en)
|
2005-08-19 |
2015-04-28 |
Wyeth Llc |
Antagonist antibodies against GDF-8 and their uses in the treatment of ALS and other disorders associated with GDF-8
|
JP2009510102A
(en)
|
2005-09-29 |
2009-03-12 |
ヴァイラル ロジック システムズ テクノロジー コーポレーション |
Immunomodulatory compositions and uses thereof
|
CA2625773C
(en)
|
2005-10-14 |
2015-05-12 |
Fukuoka University |
Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
|
BRPI0617664B8
(en)
*
|
2005-10-21 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
use of an antibody recognizing IL-6 for the production of a pharmaceutical composition to treat myocardial infarction or suppress left ventricular remodeling after myocardial infarction
|
ES2577292T3
(en)
|
2005-11-07 |
2016-07-14 |
Genentech, Inc. |
Binding polypeptides with diversified VH / VL hypervariable sequences and consensus
|
AR057582A1
(en)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
|
WO2007060411A1
(en)
|
2005-11-24 |
2007-05-31 |
Ucb Pharma S.A. |
Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
|
WO2007061029A1
(en)
|
2005-11-25 |
2007-05-31 |
Keio University |
Therapeutic agent for prostate cancer
|
WO2007074880A1
(en)
|
2005-12-28 |
2007-07-05 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing stabilizing preparation
|
HUE034269T2
(en)
|
2005-12-29 |
2018-02-28 |
Janssen Biotech Inc |
Human anti-il-23 antibodies, compositions, methods and uses
|
EP1990060B1
(en)
*
|
2006-01-27 |
2016-09-28 |
Keio University |
Therapeutic agents for diseases associated involving choroidal neovascularization
|
AU2007212147A1
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
JP4294082B2
(en)
|
2006-03-23 |
2009-07-08 |
協和発酵キリン株式会社 |
Agonist antibody to human thrombopoietin receptor
|
DK3056568T3
(en)
|
2006-03-31 |
2021-11-01 |
Chugai Pharmaceutical Co Ltd |
PROCEDURES FOR CONTROL OF THE BLOOD PHARMACOKINETICS OF ANTIBODIES
|
ES2654040T3
(en)
|
2006-03-31 |
2018-02-12 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for the purification of bispecific antibodies
|
NZ611859A
(en)
|
2006-04-05 |
2014-12-24 |
Abbvie Biotechnology Ltd |
Antibody purification
|
WO2007116962A1
(en)
|
2006-04-07 |
2007-10-18 |
Osaka University |
Muscle regeneration promoter
|
WO2007137984A2
(en)
|
2006-05-25 |
2007-12-06 |
Glaxo Group Limited |
Modified humanised anti-interleukin-18 antibodies
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
MX2008014804A
(en)
|
2006-06-02 |
2009-01-27 |
Regeneron Pharma |
High affinity antibodies to human il-6 receptor.
|
CN101500608A
(en)
|
2006-06-08 |
2009-08-05 |
中外制药株式会社 |
Preventive or remedy for inflammatory disease
|
US8629244B2
(en)
|
2006-08-18 |
2014-01-14 |
Ablynx N.V. |
Interleukin-6 receptor binding polypeptides
|
CA3163418A1
(en)
|
2006-10-06 |
2008-05-22 |
Jeffrey S. Isenberg |
Prevention of tissue ischemia, related methods and compositions
|
US20100034194A1
(en)
|
2006-10-11 |
2010-02-11 |
Siemens Communications Inc. |
Eliminating unreachable subscribers in voice-over-ip networks
|
TWI438208B
(en)
|
2007-01-23 |
2014-05-21 |
Chugai Pharmaceutical Co Ltd |
Agents for suppressing chronic rejection reaction
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
EP2155790A1
(en)
|
2007-05-31 |
2010-02-24 |
Genmab A/S |
Method for extending the half-life of exogenous or endogenous soluble molecules
|
BRPI0813954A2
(en)
|
2007-06-29 |
2020-10-06 |
Quest Diagnostics Investments Incorporated |
analysis of amino acids in the body fluid through liquid chromatography-mass spectrometry
|
WO2009010539A2
(en)
|
2007-07-19 |
2009-01-22 |
Ablynx. N.V. |
Receptor for interleukin-6 (il-6) from macaca fascicularis
|
EP2174667B1
(en)
|
2007-07-26 |
2017-01-04 |
Osaka University |
Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
|
EP2031064A1
(en)
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Method for increasing protein titres
|
AU2008298904B2
(en)
|
2007-09-14 |
2014-10-16 |
Amgen Inc. |
Homogeneous antibody populations
|
WO2009041734A1
(en)
|
2007-09-26 |
2009-04-02 |
Kyowa Hakko Kirin Co., Ltd. |
Agonistic antibody against human thrombopoietin receptor
|
CL2008002886A1
(en)
|
2007-09-26 |
2009-12-04 |
Chugai Pharmaceutical Co Ltd |
Constant region of a human antibody; anti-interleukin-6 (yl-6) receptor antibody and pharmaceutical composition comprising it.
|
PE20140132A1
(en)
|
2007-09-26 |
2014-02-14 |
Chugai Pharmaceutical Co Ltd |
IL-6 ANTI-RECEPTOR ANTIBODY
|
CN106519025B
(en)
|
2007-09-26 |
2021-04-23 |
中外制药株式会社 |
Method for changing isoelectric point of antibody by using amino acid substitution of CDR
|
AU2008305851B2
(en)
|
2007-09-28 |
2014-12-18 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-glypican-3 antibody having improved kinetics in plasma
|
EP2196220B1
(en)
|
2007-10-02 |
2014-12-03 |
Chugai Seiyaku Kabushiki Kaisha |
Inhibting anti-IL-6 receptor antibody for treating graft-versus-host disease
|
JO3076B1
(en)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
Immunotherapy regimes dependent on apoe status
|
BRPI0821110B8
(en)
|
2007-12-05 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
anti-nr10/il31ra neutralizing antibody, pharmaceutical composition comprising said antibody and use thereof
|
US8414893B2
(en)
|
2007-12-21 |
2013-04-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
CN101952454B
(en)
|
2008-02-08 |
2014-06-04 |
米迪缪尼有限公司 |
Anti-IFNAR1 antibodies with reduced Fc ligand affinity
|
KR102469853B1
(en)
|
2008-04-11 |
2022-11-22 |
추가이 세이야쿠 가부시키가이샤 |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
EP2816059A1
(en)
|
2008-05-01 |
2014-12-24 |
Amgen, Inc |
Anti-hepcidin antibodies and methods of use
|
CA2728243C
(en)
|
2008-06-05 |
2020-03-10 |
National Cancer Center |
Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
|
TWI440469B
(en)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
WO2010065079A2
(en)
|
2008-11-25 |
2010-06-10 |
Alder Biopharmaceuticals, Inc. |
Antibodies to il-6 and use thereof
|
WO2010098863A1
(en)
|
2009-02-26 |
2010-09-02 |
Lpath, Inc. |
Humanized platelet activating factor antibody design using anti-lipid antibody templates
|
JP4809930B2
(en)
|
2009-03-19 |
2011-11-09 |
中外製薬株式会社 |
Rheumatoid arthritis treatment
|
JP5787446B2
(en)
|
2009-03-19 |
2015-09-30 |
中外製薬株式会社 |
Antibody constant region variants
|
WO2010107110A1
(en)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
Antibody constant region variant
|
TWI440470B
(en)
|
2009-03-19 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Pharmaceutical formulation containing improved antibody molecules
|
SG10201404340TA
(en)
|
2009-07-31 |
2014-10-30 |
Shin Maeda |
Cancer metastasis inhibitor
|
WO2011037158A1
(en)
|
2009-09-24 |
2011-03-31 |
中外製薬株式会社 |
Modified antibody constant regions
|
TWI505838B
(en)
|
2010-01-20 |
2015-11-01 |
Chugai Pharmaceutical Co Ltd |
Stabilized antibody
|
WO2011094593A2
(en)
|
2010-01-28 |
2011-08-04 |
Ab Biosciences, Inc. |
Novel lowered affinity antibodies and methods of marking the same
|
US10435458B2
(en)
|
2010-03-04 |
2019-10-08 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variants with reduced Fcgammar binding
|
WO2011111007A2
(en)
|
2010-03-11 |
2011-09-15 |
Rinat Neuroscience Corporation |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
|
TWI667257B
(en)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
Antibodies with modified affinity to fcrn that promote antigen clearance
|
EP4115906A1
(en)
|
2010-05-28 |
2023-01-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antitumor t cell response enhancer
|
JP5904552B2
(en)
|
2010-05-28 |
2016-04-13 |
国立研究開発法人国立がん研究センター |
Pancreatic cancer treatment
|
EP3351559A3
(en)
*
|
2010-11-08 |
2018-10-31 |
F. Hoffmann-La Roche AG |
Subcutaneously administered anti-il-6 receptor antibody
|
EP2639305A4
(en)
|
2010-11-11 |
2014-04-23 |
Sysmex Corp |
Markers for detecting human follicular helper t cells and method for detecting human follicular helper t cells
|
AU2011337704B2
(en)
|
2010-11-30 |
2017-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
MX352889B
(en)
|
2011-02-25 |
2017-12-13 |
Chugai Pharmaceutical Co Ltd |
Fcîriib-specific fc antibody.
|
KR20140022815A
(en)
|
2011-02-28 |
2014-02-25 |
제넨테크, 인크. |
Biological markers and methods for predicting response to b-cell antagonists
|
TW201817745A
(en)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
|
WO2013047748A1
(en)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
JP6271251B2
(en)
|
2011-10-05 |
2018-01-31 |
中外製薬株式会社 |
An antigen-binding molecule that promotes elimination of an antigen containing a sugar chain receptor-binding domain from plasma
|
WO2013081143A1
(en)
|
2011-11-30 |
2013-06-06 |
中外製薬株式会社 |
Drug containing carrier into cell for forming immune complex
|
JP6138108B2
(en)
|
2012-02-24 |
2017-05-31 |
中外製薬株式会社 |
Antigen-binding molecule that promotes disappearance of antigen via FcγRIIB
|
US20150353630A1
(en)
|
2012-05-30 |
2015-12-10 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for eliminating aggregated antigens
|
WO2014028354A1
(en)
|
2012-08-13 |
2014-02-20 |
Regeneron Pharmaceuticals, Inc. |
Anti-pcsk9 antibodies with ph-dependent binding characteristics
|
US9321686B2
(en)
|
2013-03-15 |
2016-04-26 |
Forta Corporation |
Reinforcement fiber coating compositions, methods of making and treating, and uses for improved adhesion to asphalt and portland cement concrete
|
EP2968985A2
(en)
|
2013-03-15 |
2016-01-20 |
Amgen, Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
US11267868B2
(en)
|
2013-04-02 |
2022-03-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
EP3009518B1
(en)
|
2013-06-11 |
2020-08-12 |
National Center of Neurology and Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
US9628690B2
(en)
*
|
2014-10-21 |
2017-04-18 |
Gopro, Inc. |
Camera controller with context-sensitive interface
|
TWI805046B
(en)
*
|
2015-02-27 |
2023-06-11 |
日商中外製藥股份有限公司 |
Use of IL-6 receptor antibody for preparing pharmaceutical composition
|
WO2016186154A1
(en)
|
2015-05-19 |
2016-11-24 |
国立研究開発法人国立精神・神経医療研究センター |
Method for determining application of novel therapy to multiple sclerosis (ms) patient
|
US10943336B2
(en)
|
2016-08-04 |
2021-03-09 |
Intel Corporation |
Tone-mapping high dynamic range images
|